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Background and purpose   Activated platelets release a cocktail 
of growth factors, some of which are thought to stimulate repair. 
We investigated whether the use of autologous platelet gel (PG) in 
total knee arthroplasty (TKA) would improve wound healing and 
knee function, and reduce blood loss and the use of analgesics. 
Patients and methods   102 patients undergoing TKA were ran-
domly assigned to a PG group (n = 50) or to a control (C) group 
(n = 52). The primary analysis was based on 73 participants (PG: 
32; C: 41) with comparison of postoperative wound scores, VAS, 
WOMAC, knee function, use of analgesics, and the pre- and post-
operative hemoglobin values after a follow-up of 3 months. 29 
participants were excluded due to insufficient data.
Results   The characteristics of the protocol-compliant patients 
were similar to those of the patients who were excluded. Analysis 
was per protocol and focused on the remaining 73 patients. At 
baseline and after 3 months of follow-up, there were no statisti-
cally significant differences between both groups regarding age, 
height, weight, sex, side of operation, platelet count, hemoglobin 
values, severity of complaints (WOMAC), and level of pain.
Interpretation   In our patients undergoing TKA, application 
of PG to the wound site did not promote wound healing. Also, we 
found that PG had no effect on pain, knee function, or hemoglo-
bin values.

Identification of methods to enhance or accelerate wound heal-
ing may be important, especially in high-risk patients (e.g. with 
type 1 diabetes mellitus, tobacco use, or previously irradiated 
tissue). The requirement for growth factors within the wound-
healing cascade has been confirmed (Krupski et al. 1991, Hos-
good 1993, Adler and Kent 2002). In a canine model, treat-
ment with autologous blood platelet concentrate was found 
to enhance and accelerate early wound healing (Sclafani et 
al. 2005). In humans, autologous blood platelet concentrate 
was shown to increase bone formation in maxillofacial sur-
gery (Marx et al. 1998). Since this latter result was regarded as 
a general stimulation of repair rather than a specific increase 
in bone formation, we investigated in a double-blind random-
ized trial whether the application of a platelet concentrate (in 
spray form) might improve the repair of wounds after TKA. 
The primary outcome parameter was wound healing, but we 
also studied the effects on knee function, use of analgesics, 
and hemoglobin values.
Patients and methods
This double-blind, randomized study involved 102 con-
secutive patients scheduled for primary unilateral TKA for 
osteoarthritis between June 2005 and March 2007.
All procedures took place in a training hospital using the 
same surgical procedure performed by an orthopedic consul-
tant or a supervised senior orthopedic resident. There was no 
age limit for inclusion. Criteria for participation included pain 
and radiographic knee osteoarthritis. Exclusion criteria were: 
platelet count ≤ 150 × 109/L, hemoglobin level ≤ 6.5 mmol/L, 
BMI > 33, and systemic disorders such as diabetes, rheuma-
toid arthritis, and hepatitis.
We tested the hypothesis that the application of a platelet 
concentrate (in spray form) would improve repair of wounds 
after TKA. The primary endpoint was wound healing. In addi-
tion, we determined whether there were any effects on knee 
function, use of analgesics, and hemoglobin values.
Randomization
Block randomization of the patients was performed after they 
were deemed eligible and had provided informed consent. 
Patients were randomly allocated to the PG arm or to the C 
arm. Treatment assignments (placed in sequentially numbered 
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opaque envelopes) were done by the trial managers, who also 
arranged the facilities needed for the procedure.
Surgical procedure 
The medial parapatellar approach was used, averting the patella 
laterally. A tourniquet was used. In all cases, a cemented pos-
terior cruciate retaining prosthesis (AGC; Biomet Biologics, 
Warsaw, IN) was used. After implantation of the components, 
the tourniquet was deflated and primary hemostasis was 
achieved. Before closure of the wound layers, the soft tissues 
and knee joint were rinsed with saline solution to remove all 
debris. After closure of the joint capsule, the subcutaneous tis-
sues of the patients randomized to receive PG were sprayed 
with the platelet-poor plasma (PPP) fraction (approx. 10 mL) 
and the skin was closed with staplers. We did not use a deep 
or subcutaneous drain. In all patients, the knee incision was 
dressed postoperatively with compression bandages and reha-
bilitation was started on the day after surgery. In this fashion, 
patients, nurses, and physiotherapist were all blinded as to 
which procedure was used.
Platelet-rich plasma preparation 
In the group randomized to receive PRP, the patient’s own 
platelets were collected using the GPS System (Biomet Inc.). 
This device uses a desktop-size centrifuge with disposable cyl-
inders to isolate the platelet-rich fraction from a small volume 
of the patient’s anticoagulated blood drawn at the time of the 
procedure.
First, a 60-mL syringe was filled with 7 mL of anticoagu-
lant citrate phosphate dextrose formula A and 53 mL of whole 
blood was drawn via an intravenous catheter in the medial 
cubital vein using a 17-G needle. Proper mixing with the anti-
coagulant was done by inverting the syringe 8 times. The plate-
let-rich fraction was prepared according to the instructions for 
the use of the GPS system. In brief, blood was drawn into a 
60-mL bowl of the blood cell separator and centrifuged for 15 
min at a rate of 3,200 RPM for sequestration. Approximately 
6 mL of PRP was obtained from each patient. Autologous 
thrombin was isolated from PRP and 0.17 mL of 10% cal-
cium chloride to antagonize the anticoagulant in the donated 
blood. The platelets were activated by addition of calcified 
thrombin. The total time from drawing of blood to injection 
in the patients was about 90 min. No specialized equipment 
other than the centrifuge to process the GPS disposable was 
required. A person who was certified in blood management 
performed all the procedures under sterile conditions.
Injection technique
Using a spray tip at a distance of 10–15 cm with the knee 
flexed at 90 degrees, which exposes the knee cavity, 6 mL 
PRP was applied to the dried wound site (synovium and bony 
cutting edges of femur and tibia); thereafter, the wound was 
closed in layers. After closure of the joint capsule, the subcu-
taneous tissues of the patients randomized to receive PG were 
sprayed with the platelet-poor plasma (PPP) fraction (10 mL 
approximately).
Rehabilitation
Postoperative pain relief was achieved using a standard pro-
tocol: paracetamol (3 g daily) and diclofenac (50 mg 3 times 
daily), with pantoprazol (40 mg daily) for protection against 
ulcers. All patients received thrombosis prophylaxis from a 
subcutaneous injection of 0.3 mL low-molecular-weight hepa-
rin daily before the operation, and this was continued until a 
sufficient effect of oral anticoagulants (acenocoumarol) was 
achieved. The oral anticoagulants were used up to 12 weeks 
postoperatively. Rehabilitation, which was started on the day 
after surgery using crutches, was according to the Joint Care 
program (Biomet). The physiotherapist was also blinded as to 
which procedure was used.
Wound score form
A wound score form was used for scoring wound healing 
(Table 1; see supplementary data). A pilot study showed the 
wound score form to be sufficiently reliable (K = 0.8, unpub-
lished data). The score ranged from 0 to 100, with 0 represent-
ing a dry wound without any sign of infection, and 100 repre-
senting wound leakage with signs of infection. Points relating 
to changes of wound dressings (question 2) were multiplied 
by the score from the type of wound dressing (question 1: ×1 
or ×2)]. Questions 3 and 4 were indicators of wound leak-
age, questions 5 and 7 were indicators of the type of leak-
age, and question 6 addressed wound infection parameters. 
The wound scores were measured by a trained orthopedics 
resident (medical ward) who did not know whether PG had 
been used. 
Statistics
There is little published information on whether the effect of 
application of a platelet concentrate can improve the repair of 
wounds after TKA. The purpose of this study was to investigate 
whether the application of a platelet concentrate would reduce 
25% of the wound leakage. Wound leakage was regarded as a 
binary result (leakage or no leakage).
With a bilateral alpha of 0.05 and a power of 80%, 43 
patients were required in each group to show a significant dif-
ference (α = 0.05, β = 0.8, 2n = 86). This difference is based 
on a study of Gardner et al. (2006).  
Wound scores and function scores were measured on days 
3–5, and at the regular control every 2 weeks. The function 
scores were also measured at 6 and 12 weeks postoperatively. 
For the purposes of analysis, the wound scores were dichoto-
mized according to either “wound closure” (with a score of 0; 
no leakage or signs of infection) or “wound leakage” (scores > 
0). Absolute differences in the rate of wound closure with cor-
responding confidence intervals were computed according to 
Altman (1991). Wound closure was analyzed with Chi-square 
test between the 2 groups for each day.
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Hemoglobin values were measured pre- and postopera-
tively. The drop in hemoglobin was analyzed using unpaired 
Student’s t-test.
Visual analog scale (VAS) for pain at rest and pain during 
walking was measured at intake and 6 weeks and 12 weeks 
postoperatively. The analog scores 0–10 mm (negligible), 
10–30 mm (mild), 30–50 mm (painful), 50–80 mm (moder-
ate), and 80–100 (severe) were regarded as ordinal categories. 
Analysis was focused on the changes between measurement 
points in time, using Mann-Whitney U tests. Postoperative 
frequency of use of analgesics was scored on a 5-point scale 
(never to always) preoperatively, and 6 weeks and 3 months 
postoperatively. Changes between measurement points in time 
were analyzed using Mann-Whitney tests.
The range of motion of the operated knee was analyzed on 
the second day, the third day, and the fourth day, and also 2 
weeks, 6 weeks, and 3 months postoperatively using ANOVA 
for repeated measurements. WOMAC function scores were 
measured preoperatively, and 6 and 12 weeks postoperatively. 
Analysis focused on changes between measurement points in 
time, using Mann-Whitney U tests. A trained medical person 
who was blinded as to the treatment group measured all scores.
 All data analyses were intended to be carried out according 
to a pre-established plan of analysis based on the principle of 
intention to treat. The significance level was set at p = 0.05. 
SPSS software version 16.0 for Windows was used.
Ethics
All patients had to be able to read and understand the proto-
col and the informed consent document. The Medical-Ethi-
cal Commission (METC) and the National and Institutional 
Review Board approved the study (METC protocol number 
04-17; date of approval October 27, 2004). The trial was per-
formed in compliance with the Helsinki Declaration (2000) 
and Good Clinical Practice (1997).
Results
From June 2005 to March 2007, a total of 111 patients with an 
indication for TKA were included in the study. 9 patients had 
to be excluded because of inclusion errors. Analysis was per 
protocol and focused on the remaining 102 patients. This was 
done according to a pre-established analysis plan based on the 
principle of intention to treat: 50 TKA patients were treated 
with PG and 52 were treated without PG. Patient characteris-
tics at baseline were similar in the 2 groups (Table 2). 
Due to a reorganization of the patient’s ward, however, no 
or partial measurements were recorded for a number of the 
study patients during their hospital stay. Missing data were 
attributed based on the “last known result carried forward” 
principle.
The characteristics of the patients who were fully recorded 
were similar to those of the other patients (Table 3). Eventu-
ally, full data were recorded for 32 patients in the PG group 
and 41 patients in the C group. Analysis for possible bias 
caused by missing data showed no differences between the 
resulting groups at baseline (Table 3, Figure).
Primary endpoint (wound healing)
Both groups had normal wound healing (Table 4). No clini-
cally or statistically significant differences in wound closure 
Table 2. Patient characteristics at inclusion
 PG group  Control group
No. of patients  50  52
No. of males  13 (26%)  11 (21%)
Age, mean (SD)  77 (4.4)  78 (5.1)
Length in cm, mean (SD)  168 (9.1)  168 (8.1)
Weight in kg, mean (SD)  83 (16)  79 (12)
Platelet count in 109/L, mean (SD)  253 (63)  273 (64)
Hb in mmol/L, mean (SD)  8.6 (0.9)  8.5 (0.7)
Right side  29 (58%)  30 (59%)
WOMAC score, median (range)  49 (8–78)  43 (14–74)
Pain at rest, median (range)  3 (1–5)  3 (1–5)
Pain during activity, median (range)  4 (1–5)  4 (1–5)
Table 3. Data of the patients with and without in-hospital recorded data
 Complete   Incomplete   p-value   PG group  Control group  p-value
 recovery recovery
No. of patients  73  29     32  41 
No. of males  14 (19%)  10 (34%)  0.1   6 (19%)  8 (20%)  1
Age, mean (SD)  77 (4.8)  77 (4.8)  0.9   76 (4.1)  78 (5.2)  0.1
Length in cm, mean (SD)  167 (7.6)  169 (10.7)  0.3   166 (6.5)  168 (8.3)  0.4
Weight in kg, mean (SD)  80 (14)  81 (15)  0.8   81 (17)  80 (12)  0.6
Platelet count in 109/L, mean (SD)  269 (66)  249 (58)  0.2   261 (68)  275 (64)  0.4
Hb in mmol/L, mean (SD)  8.6 (0.8)  8.6 (0.9)  0.9   8.6 (0.8)  8.5 (0.7)  0.3
Right side 43 (59%)  16 (57%)  1   16 (50%)  27 (66%)  0.2
WOMAC score, median (range)  45 (8–76)  41 (11–76)  0.4   50 (8–76)  43 (14–74)  0.6
Pain at rest, median (range)  3 (1–5)  3 (1–5)  0.8   4 (1–5)  3 (1–5)  0.6
Pain during activity, median (range)  4 (1–5)  4 (2–5)  0.9   4 (1–5)  4 (1–5)  0.3
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were noted between the 2 groups during the hospital stay 
(third day, 95% CI: 11% to 25% difference; fourth day, 95% 
CI: 30% to 10% difference). At 2 weeks, significantly more 
patients in the control group had total wound closure than in 
the PG group (p = 0.02) (95% CI: –41% to –7% difference).
Secondary endpoints
There was a difference in the postoperative drop in levels of 
hemoglobin between the 2 groups (between-group difference: 
0.16 mmol/L, p = 0.2; 95% CI: –0.07 to 0.4 difference) (Table 
4).
Reported pain was reduced from (moderately) painful 
to mild pain 6 weeks postoperatively. There was a trend of 
greater pain reduction (both at rest and while walking) at 6 
weeks postoperatively for the C group.
The median frequency of use of medication was “some-
times”, and this remained the median answer thoughout the 
study period. There was no difference in reduction of use 
of pain medication between the PG group and the C group, 
either at 6 weeks postoperatively (p = 0.9) or at 3 months (p 
= 0.1).
As expected, during hospitalization the range of motion of 
the operated knee increased from 50 degrees 2 days after sur-
Flow chart of the patients.
Excluded due to
inclusion errors
(n=9)
Analyzed
(n=32)
Excluded (n=18)
due to incomplete data
Lost to follow-up
(n=0)
Platelet Gel group
(n=50)
Analyzed
(n=41)
Excluded (n=11)
due to incomplete data
Lost to follow-up
(n=0)
Control group
(n=52)
Randomization
(n=102)
Participants
allocated to treatment
(N=111)
Table 4. Data on the platelet gel group (PG) and the control group
  PG group Control group  95% CI  p-value
Wound closure )  n = 32 n = 41  
 Second day postoperatively   0    0    –
 Third day postoperatively    7     6      7% (–11% to 25%)  0.5
 Fourth day postoperatively    7   13    –9% (–30% to 10%)  0.4
Wound closure  n = 36  n = 46  
 2 weeks postoperatively    4   16 –24% (–41% to 7%)  0.02
Drop in Hb, mean (SD)  n = 50  n = 52  
 mmol/L   –1.58 (0.63)  –1.75 (0.58)    0.16 (–0.07 to 0.4)  0.2
Pain at rest, median (range)  n = 50  n = 52  
 At inclusion  3 (1–5)  3 (1–5)    0.8
 6 weeks  2 (1–5)  2 (1–5)    0.08
 3 months  2 (1–5)  2 (1–5)    0.8
Pain during walking, median (range) n = 50  n = 52  
 At inclusion  4 (1–5)  4 (1–5)    0.4
 6 weeks  2 (1–5)  2 (1–5)    0.07
 3 months  2 (1–5)  2 (1–5)    0.9    
Use of pain medication, median (range)  n = 50  n = 52  
 At inclusion  2 (1–5)  2 (1–5)    0.5
 6 weeks  2 (1–5)  2 (1–5)    0.9
 3 months  2 (1–5)  2 (1–5)    0.1
WOMAC score, mean (range)  n = 50  n = 52  
 At inclusion  45 (8–76)  44 (14–74)  
 6 weeks   26 (3–76)  24 (0–65)         0 (–8 to 8)  0.7
 3 months  25 (0–76)  21 (0–66)       –3 (–6 to 1)  0.4
ROM, mean (SD)  n = 32  n = 36  
 Second day postoperatively  53 (14)  50 (17)  
 Third day postoperatively  68 (13)  65 (16)  
 Fourth day postoperatively  72 (13)  73 (14)    0.7
ROM, mean (SD)  n = 34  n = 45  
 2 weeks postoperatively    91 (13)    89 (13)  
 6 weeks postoperatively    99 (11)  100 (13)  
 3 months postoperatively  102 (12)  101 (12)    0.9
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gery to 75 degrees at discharge from hospital. During these 
days, no benefit was seen for the PG group (2-way ANOVA, 
p = 0.7). At 2 weeks, 6 weeks, and up to 3 months of follow-up, 
no differences were seen between the two groups (p = 0.9).
At 6 weeks postoperatively, the self-rated knee function 
(WOMAC score) had increased by 20 points, but the recovery 
rate between the two groups was similar (Mann-Whitney U 
test, p = 0.7; 95% CI: –8 to 8 difference); similarly, there were 
no differences between groups at the 3-month follow-up (95% 
CI: –6 to 1 difference).
Complications
After discharge from hospital, superficial wound infections 
occurred in 2 patients (1 in each group, both of which were 
caused by coagulase-negative Staphylococcus); these infec-
tions were treated successfully with antibiotics. No deep 
infections were seen.
Discussion
In this randomized study, we found no effect on wound heal-
ing of platelet gel (PG) used after TKA.
 PG is promoted as an ideal autologous biological blood-
derived product that can be exogenously applied to various 
tissues where it releases high concentrations of platelet growth 
factors that enhance wound healing. In addition, PG has anti-
microbial properties that may contribute to the prevention of 
infections (Everts et al. 2007). When platelets become acti-
vated, growth factors are released and they initiate the body’s 
natural healing response. 
The actual quantity of platelets needed to achieve an 
improved outcome when PG is used is still unknown. Marx 
et al. (1998) found that a 3–4 times higher platelet count 
improved the mandibular continuity defects. The GPS system 
that we used produces a 6–8 times higher platelet count. 
Much higher concentrations might have an inhibitory effect 
(Weibrich et al. 2004). The activator for the platelets we used 
was a mixture of thrombin and calcium chloride. After combin-
ing these substances, platelet-rich gel is formed and numerous 
regulatory molecules and antimicrobial proteins are released 
to the injury site (Wrotniak et al. 2007). Thrombin derived 
from bovine plasma is used in the USA, despite the fact that 
bovine thrombin was associated years ago with the develop-
ment of antibodies to thrombin and factor V, which had led 
to recurrent bleeding in patients who were exposed (Zehnder 
and Leung 1990). Alternatively, the platelets can be activated 
by autologous thrombin, produced with commercially avail-
able thrombin kits (Everts et al. 2006 b, c). Tsay et al. (2005) 
described the use of a synthetic peptide that mimics thrombin, 
known as peptide-6 SFLLRN (TRAP). 
Using the GPS system, the patient’s own platelets (which 
travel through the bloodstream) can be collected into a highly 
concentrated formula.
We found a slight difference in the drop in hemoglobin: 0.16 
mmol/L. This was 10% of the total drop. The mean hemo-
globin before operation was 8.6 mmol/L. After operation, the 
hemoglobin in the PG group dropped to 7.1 mmol/L and in the 
control group it dropped to 7.0 mmol/L. This finding contrasts 
with an earlier report, which might be explained by differences 
in the technique and methodology. For example, Everts et al. 
(2006a) used a PG and fibrin sealant technique, a preparation 
that differs from our technique. Moreover, their trial included 
more patients and the hemoglobin values were scored not only 
on the first postoperative day (as in our study) but also on days 
2–4 after surgery, and again on the day of hospital discharge. 
Everts et al. only scored function during the first 5 days and on 
the day of discharge, whereas we scored function on the first 4 
days, and at 2, 6, and 12 weeks postoperatively. 
The beneficial effects of concentrated growth factors are 
said to reduce wound leakage by 25%, minimizing the need 
for postoperative blood transfusion, reducing the risk of post-
operative infections, and promoting faster functional rehabili-
tation with less pain (Floryan and Berghoff 2004, Gardner et 
al. 2006). Most reports on PG have involved its use for healing 
chronic wounds (Hom and Maisel 1992, Hosgood 1993, Wang 
et al. 1996, Powell et al. 2001, Crovetti et al. 2004). To our 
knowledge, no blind randomized study has been performed 
previously. 
The type of wound dressing is also important. It has been 
shown that with the use of occlusive dressings, both re-epitheli-
alization and subsequent collagen synthesis are 2–6 times faster 
than they are in wounds exposed to air. At the cellular level, 
dressings assist wound healing by creating a hypoxic wound 
environment in which fibroblasts proliferate and angiogenesis 
occurs more rapidly (Fletcher et al. 2007). The proper timing 
of dressing removal remains a controversial subject. Studies 
on clean, and clean contaminated, wounds have shown no dif-
ference in infection rates between whether the dressing was 
removed on the first postoperative day or at the time of suture 
removal (Chrintzet al. 1989, Meylan and Tschantz 2001). In 
our patients, all wounds were dressed with sealed bandages 
directly after surgery and undressed on the second day after 
surgery; no beneficial effect of PG was seen. The use of PG 
has shown good results in wounds that are difficult to heal 
compared to normal wound treatment (Margolis et al. 2001, 
Henderson et al. 2003, Mazzuco et al. 2004), but exogenously 
applied platelets have no hemostatic effect. They have poor ten-
sile strength to accomplish sealing of the wound. Altmeppen et 
al. (2004) showed that an autologous platelet-enriched plasma 
cannot be used as a glue in the common sense to seal stitches or 
prostheses. Platelet gels, however, have a high concentration of 
platelets that release the bioactive proteins and growth factors 
that are necessary to initiate and accelerate tissue repair and 
enhance dermal and epidermal regeneration.
We used a specially designed wound scoring system; to our 
knowledge, no measure of wound leakage has previously been 
described for this type of study.
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Several of the patients had incomplete datasets. This was 
because of integration of 2 hospitals into one during the 
second half of the trial; we underestimated the deleterious 
effect of this reorganization on the quality of data collection 
at the ward level. There is no clear explanation for the differ-
ence between the rate at which patients from both groups were 
not recorded; we can only assume that this was coincidental. 
Between-group analysis of patient characteristics at baseline 
did not show any statistically significant differences in the 
patients with or without complete data recoding. Due to this 
dropout of data, we had a severe loss of statistical power with 
regard to our primary outcome measure (wound closure). Our 
results regarding wound closure do, however, follow a similar 
trend to those of all secondary outcome measures and are in 
accordance with our clinical observations, thus strengthening 
our conclusion. Another limitation of our study was that we 
did not investigate the effect of varying platelet and fibrinogen 
concentrations.
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